Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type8 I4 K0 Y. e# ^- I4 K/ r
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
! H; e6 S- E1 O+ Author Affiliations
6 d, a$ r# ^. i# a% ]$ O7 a2 E8 t, Q8 d
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 5 V6 B! B) |( T* p6 D$ L
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 5 X3 V1 G! d2 i
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 m2 Y1 Y# O$ h$ P5 o2 ^3 ?0 M
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan , \1 ?# Y4 u. ]% k8 N8 h
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 4 w) y4 b. ?& ^) k
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
( W5 m) O( A6 \. P, q# m' w: h' j7Kinki University School of Medicine, Osaka 589-8511, Japan
; K7 ^+ K, a7 T: p1 f8Izumi Municipal Hospital, Osaka 594-0071, Japan . N6 K1 h5 f0 W% }
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
' k4 p7 a6 T& G) s/ E3 A' j Z6 dCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
6 m: B, n* J# `$ z$ `( {AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. , u5 h1 S4 C1 M! [7 G
, V8 H' F0 S5 M) s
|